ARCHimedes Vascular, LLC has secured a major milestone in the Pharmaceuticals, Medical Devices and Healthcare industry with a newly patented treatment for hypertension. This innovation focuses on the patent titled ‘Aortic arch baroreceptor implants for treatment of hypertension’. The patent describes a specialized medical device configured for placement in a target region of an aortic arch to induce a baroreflex response.
Advancing Baroreflex Activation Therapy
Abstract: Implant devices for hypertension and methods of treatment are provided. Implant devices are configured for placement in a target region of an aortic arch of the patient, thereby engaging arterial walls in the target region sufficiently to stretch and/or tension arterial walls, thereby inducing the baroreflex response. Such implants can include one or more expandable structures configured to engage an elongated target region in the aortic arch. The target region can extend along a majority of the aortic arch including a cylindrical segment of aortic arch between the left common carotid artery and the left subclavian artery. An elongated target zone can further extend at least between the brachiocephalic artery takeoff and the left subclavian artery takeoff. Such embodiments can utilize one or more expandable structures with a non-circular cross-section that stretch and reshape the arterial walls to induce tension in the arterial walls, thereby generating a robust baroreflex response.
Award Recognition: Swanson Reed Patent of the Month
The selection of ARCHimedes Vascular, LLC for the Swanson Reed Patent of the Month in March 2026 highlights a significant leap forward in the treatment of resistant hypertension. While traditional pharmaceutical interventions often struggle with patient compliance or systemic side effects, this mechanical approach directly leverages the body’s internal regulatory systems. By targeting the aortic arch with a precision-engineered implant, the technology offers a more consistent and sustainable method for lowering blood pressure than systemic drug therapies.
What makes this invention particularly outstanding is the sophisticated engineering of the non-circular cross-section expandable structures. Most vascular implants are designed to maintain a vessel’s natural circularity: however, this patent flips that logic by intentionally reshaping the arterial wall to create specific tension. This mechanical stimulation mimics the signals the brain receives when blood pressure is high, effectively “”tricking”” the nervous system into lowering blood pressure naturally. This level of physiological integration represents the cutting edge of medical device design.
Furthermore, the patent addresses a critical clinical gap by targeting the specific zone between the left common carotid and the left subclavian artery. By focusing on this elongated target region, the device ensures a more robust and reliable baroreflex response than previous, smaller-scale attempts. This comprehensive coverage of the aortic arch demonstrates a deep understanding of vascular anatomy and clinical efficacy, making it a deserving winner in the Pharmaceuticals, Medical Devices and Healthcare category.
R&D Tax Credit Alignment in the USA
To qualify for the R&D tax credit in the USA under Section 41 of the Internal Revenue Code, a company must satisfy the Four-Part Test. The development of this patent by ARCHimedes Vascular aligns with these criteria through its focus on technical uncertainty and the process of experimentation. Specifically, the project meets the Permissible Purpose test by improving the functionality of hypertension treatments: the Elimination of Uncertainty test by determining the optimal design for arterial tension: the Process of Experimentation test through iterative geometry testing: and the Technological in Nature test by relying on engineering and biological sciences.
Practical R&D Applications
- Geometric Optimization Studies: Conducting iterative testing and computational fluid dynamics (CFD) modeling to determine which non-circular cross-section (such as elliptical or lobed shapes) produces the highest baroreceptor sensitivity while maintaining blood flow stability.
- Biocompatibility and Material Stress Testing: Researching and testing various Nitinol or polymer-based alloys to ensure the implant can maintain constant tension on the aortic wall for decades without experiencing material fatigue or inducing adverse immune responses like intimal hyperplasia.
- Delivery System Prototype Development: Designing and engineering the specialized catheter-based delivery system required to precisely deploy an elongated, non-circular device within the high-pressure environment of the aortic arch, including the development of re-sheathable mechanisms for repositioning during surgery.
